Virginia’s legislature passed menopause at work protections. The Governor substituted a study. That sequence is the most significant policy development in this menopause at work legislation series since it launched.
The condition established across this series applies here with one material difference: the legislature passed the protection. The Governor substituted a study.
That sequence is worth reading carefully before examining what it means, because it confirms something the series has been documenting since Day 1. When formal systems encounter the perimenopause and menopause disclosure gap, they do not resolve it. They document it.
What the Legislature Passed
The Virginia General Assembly passed HB1173 and SB258, which would have amended the Virginia Human Rights Act to make menopause and perimenopause a protected characteristic, prohibited employers from treating women differently because of where they are in their menopause transition, and required reasonable accommodations for known limitations. Both bills passed with strong bipartisan margins.
SB790, which requires health insurers to cover medically necessary treatments for menopause and perimenopause symptoms, was signed and approved April 13, 2026. That provision is law, effective July 1, 2026.
What Governor Spanberger Did
On April 11, 2026, Governor Spanberger proposed a substitute for HB1173 and SB258. The substitute removes the protected characteristic designation, removes the accommodation mandate, and replaces both with a single directive: the Commissioner of Labor and Industry, in consultation with the Commissioner of Health, shall conduct a study on menopause and perimenopause in the workforce and submit findings to the Governor and General Assembly by July 1, 2028.
The Governor did not veto the bills, she substituted them. The legislature’s protection became an executive study. However, Virginia already had a menopause workplace study underway at the Department of Labor and Industry before HB1173 reached the Governor’s desk. That study generated expert comment from researchers, advocates, and policy analysts, including a formal comment submitted to DOLI on behalf of Lozen Advisory, documenting the measurement gap that disclosure-dependent studies structurally cannot close. The Governor’s substitute for HB1173 orders a second study from the same agency, reporting to the same government, by 2028.
Will The Study Discover Something New?
The substitute study will examine menopause-related accommodations in employment environments, the scope of existing policies, health insurance coverage, access to health care professionals, awareness policies, and health care spending accounts.
Each of those categories shares a structural condition: they measure what employees have disclosed, requested, or formally utilized. The Day 3 analysis of Virginia’s original workforce study mandate documented this constraint precisely. The substitute does not change it. It formalizes it inside a different instrument.
A study that draws from accommodation requests, healthcare utilization, and leave records will find what entered those systems. The Day 7 analysis of New York’s S7495, a study bill with identical category boundaries, establishes what that means: the population named in the findings is excluded from the measurement the findings commissioned.
Virginia named these women in the legislative record. The substitute then directed a study whose instruments cannot reach them.
What the Governor’s Substitute Confirms
Systems do not require intent. They require incentive and opportunity.
The Governor’s substitute is not evidence of bad faith. It is evidence of how formal systems respond when asked to extend protection into a domain where the disclosure condition makes the population difficult to measure. The response is: study it first. Measure before acting. Produce a record before producing a protection.
That response is structurally identical to the pattern the legislative analysis series has documented across every bill it has examined. The legislature names the women. The system asks for data about the women. The data instrument excludes the women who do not enter formal systems. The findings confirm manageable reported impact. The protection waits.
SB790, the insurance coverage bill, was signed because it operates at the clinical layer, not the employment layer. Coverage requires a woman to seek treatment under her name. That is a disclosure condition she controls outside the employment relationship. The Governor signed the bill that does not require her employer to know.
SB790 Is Law. The Workplace Protection Is Not.
SB790 is law, effective July 1, 2026. Insurance coverage for medically necessary menopause and perimenopause treatment is meaningful for the women who seek clinical care and whose providers are equipped to give it. The Maryland SB892 analysis documented the clinical recognition gap that precedes coverage. Coverage does not resolve the gap. It removes one barrier for women who have already crossed the others.
The protection HB1173 and SB258 would have provided, the prohibition on discriminatory treatment and the accommodation mandate, does not exist in Virginia law. What exists is a study due July 1, 2028, operating on the same disclosure-dependent instruments the series has been examining since Day 1.
That calculation has a name. The pattern it produces across the organizational record has a name too. Both are documented in the Invisible Attrition℠ framework.
She was never silent. She decided.
See the full menopause legislation tracker.
Commission a Strategic Briefing
Menopause-at-work legislation is creating a new workforce-risk record for employers. Lozen Advisory advises senior executives, CFOs, General Counsel, and corporate boards on accommodation exposure, disclosure-dependent measurement gaps, retention risk, and the organizational consequences of policies that activate only after employee disclosure.
